Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents: assessment of adverse events in non‐randomised studies

Ole Jakob Storebø; Nadia Pedersen; Erica Ramstad; Maja Lærke Kielsholm; Signe Sofie Nielsen; Helle B. Krogh; Carlos R. Moreira‐Maia; Frederik L. Magnusson; Mathilde Holmskov; Trine Gerner; Maria Skoog; Susanne Rosendal; Camilla Groth; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Sasja J. Håkonsen; Lise Aagaard; Erik Simonsen; Christian Gluud

doi:10.1002/14651858.CD012069.pub2

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents: assessment of adverse events in non‐randomised studies

Ole Jakob Storebø^*, Nadia Pedersen, Erica Ramstad, Maja Lærke Kielsholm, Signe Sofie Nielsen, Helle B. Krogh, Carlos R. Moreira‐Maia, Frederik L. Magnusson, Mathilde Holmskov, Trine Gerner, Maria Skoog, Susanne Rosendal, Camilla Groth, Donna Gillies, Kirsten Buch Rasmussen, Dorothy Gauci, Morris Zwi, Richard Kirubakaran, Sasja J. Håkonsen, Lise AagaardErik Simonsen, Christian Gluud

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Review › Forskning › peer review

Abstract

Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in childhood. The psychostimulant methylphenidate is the most frequently used medication to treat it. Several studies have investigated the benefits of methylphenidate, showing possible favourable effects on ADHD symptoms, but the true magnitude of the effect is unknown. Concerning adverse events associated with the treatment, our systematic review of randomised clinical trials (RCTs) demonstrated no increase in serious adverse events, but a high proportion of participants suffered a range of non‐serious adverse events.

Originalsprog	Engelsk
Artikelnummer	CD012069
Tidsskrift	Cochrane Database of Systematic Reviews
Vol/bind	2018
Udgave nummer	5
DOI	https://doi.org/10.1002/14651858.CD012069.pub2
Status	Udgivet - 2018

Adgang til dokumentet

10.1002/14651858.CD012069.pub2

Citationsformater

Storebø, O. J., Pedersen, N., Ramstad, E., Kielsholm, M. L., Nielsen, S. S., Krogh, H. B., Moreira‐Maia, C. R., Magnusson, F. L., Holmskov, M., Gerner, T., Skoog, M., Rosendal, S., Groth, C., Gillies, D., Rasmussen, K. B., Gauci, D., Zwi, M., Kirubakaran, R., Håkonsen, S. J., ... Gluud, C. (2018). Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents: assessment of adverse events in non‐randomised studies. Cochrane Database of Systematic Reviews, 2018(5), Artikel CD012069. https://doi.org/10.1002/14651858.CD012069.pub2

@article{9786e8a8d6dc442ca9520474edf8f71c,

title = "Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents: assessment of adverse events in non‐randomised studies",

abstract = "Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in childhood. The psychostimulant methylphenidate is the most frequently used medication to treat it. Several studies have investigated the benefits of methylphenidate, showing possible favourable effects on ADHD symptoms, but the true magnitude of the effect is unknown. Concerning adverse events associated with the treatment, our systematic review of randomised clinical trials (RCTs) demonstrated no increase in serious adverse events, but a high proportion of participants suffered a range of non‐serious adverse events.",

author = "Storeb{\o}, {Ole Jakob} and Nadia Pedersen and Erica Ramstad and Kielsholm, {Maja L{\ae}rke} and Nielsen, {Signe Sofie} and Krogh, {Helle B.} and Moreira‐Maia, {Carlos R.} and Magnusson, {Frederik L.} and Mathilde Holmskov and Trine Gerner and Maria Skoog and Susanne Rosendal and Camilla Groth and Donna Gillies and Rasmussen, {Kirsten Buch} and Dorothy Gauci and Morris Zwi and Richard Kirubakaran and H{\aa}konsen, {Sasja J.} and Lise Aagaard and Erik Simonsen and Christian Gluud",

year = "2018",

doi = "10.1002/14651858.CD012069.pub2",

language = "English",

volume = "2018",

journal = "Cochrane Database of Systematic Reviews",

issn = "1465-1858",

publisher = "John Wiley and Sons Ltd",

number = "5",

}

Storebø, OJ, Pedersen, N, Ramstad, E, Kielsholm, ML, Nielsen, SS, Krogh, HB, Moreira‐Maia, CR, Magnusson, FL, Holmskov, M, Gerner, T, Skoog, M, Rosendal, S, Groth, C, Gillies, D, Rasmussen, KB, Gauci, D, Zwi, M, Kirubakaran, R, Håkonsen, SJ, Aagaard, L, Simonsen, E & Gluud, C 2018, 'Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents: assessment of adverse events in non‐randomised studies', Cochrane Database of Systematic Reviews, bind 2018, nr. 5, CD012069. https://doi.org/10.1002/14651858.CD012069.pub2

TY - JOUR

T1 - Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents

T2 - assessment of adverse events in non‐randomised studies

AU - Storebø, Ole Jakob

AU - Pedersen, Nadia

AU - Ramstad, Erica

AU - Kielsholm, Maja Lærke

AU - Nielsen, Signe Sofie

AU - Krogh, Helle B.

AU - Moreira‐Maia, Carlos R.

AU - Magnusson, Frederik L.

AU - Holmskov, Mathilde

AU - Gerner, Trine

AU - Skoog, Maria

AU - Rosendal, Susanne

AU - Groth, Camilla

AU - Gillies, Donna

AU - Rasmussen, Kirsten Buch

AU - Gauci, Dorothy

AU - Zwi, Morris

AU - Kirubakaran, Richard

AU - Håkonsen, Sasja J.

AU - Aagaard, Lise

AU - Simonsen, Erik

AU - Gluud, Christian

PY - 2018

Y1 - 2018

N2 - Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in childhood. The psychostimulant methylphenidate is the most frequently used medication to treat it. Several studies have investigated the benefits of methylphenidate, showing possible favourable effects on ADHD symptoms, but the true magnitude of the effect is unknown. Concerning adverse events associated with the treatment, our systematic review of randomised clinical trials (RCTs) demonstrated no increase in serious adverse events, but a high proportion of participants suffered a range of non‐serious adverse events.

AB - Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in childhood. The psychostimulant methylphenidate is the most frequently used medication to treat it. Several studies have investigated the benefits of methylphenidate, showing possible favourable effects on ADHD symptoms, but the true magnitude of the effect is unknown. Concerning adverse events associated with the treatment, our systematic review of randomised clinical trials (RCTs) demonstrated no increase in serious adverse events, but a high proportion of participants suffered a range of non‐serious adverse events.

U2 - 10.1002/14651858.CD012069.pub2

DO - 10.1002/14651858.CD012069.pub2

M3 - Review

SN - 1465-1858

VL - 2018

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 5

M1 - CD012069

ER -

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents: assessment of adverse events in non‐randomised studies

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater